IL10 and uveitis: (i) Regulatory B cell (Breg) therapy: Breg immunotherapy with as few as 5x106 cells is sufficient to suppress uveitis by inhibiting Th17/Th1 lymphocytes and converting conventional lymphocytes into IL-10 and/or IL-35-producing regulatory cells.